Skip to main content

Table 2 Estimation results from Cox proportional hazard models of mortality from OC and from other causes

From: Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study

Variable

Mortality from OC

Mortality from other causes

Group size

Deaths

HR

(95% CI)

Deaths

HR

(95% CI)

Year of diagnosis

 1998─2002

115

84

1.00

Ref.

13

1.00

Ref.

 2003─2007

149

106

1.17

(0.86–1.59)

12

1.16

(0.45–2.99)

 2008─2011

157

86

0.97

(0.69–1.37)

9

1.13

(0.39–3.27)

Age at diagnosis (years)

 42─59

59

30

0.67

(0.44–1.04)

1

0.18

(0.02–1.53)

 60─69

132

76

1.00

Ref.

9

1.00

Ref.

 70─79

160

120

1.53

(1.14–2.05)

14

2.49

(1.03–6.05)

 80─92

70

50

2.88

(1.98–4.20)

10

5.40

(1.99–14.65)

Duration of diabetes (years)

 0.5─ < 3

103

61

1.00

Ref.

11

1.00

Ref.

 3─ < 6

100

70

1.31

(0.91–1.90)

3

0.35

(0.09–1.36)

 6─ < 12

148

101

1.15

(0.81–1.63)

11

0.88

(0.34–2.27)

 12─ < 34

70

44

0.98

(0.61–1.57)

9

1.20

(0.42–3.44)

Stage

 Local

52

9

1.00

Ref.

9

1.00

Ref.

 Advanced

330

256

9.05

(4.60–17.82)

19

0.80

(0.32–2.01)

 Unknown

39

11

1.60

(0.66–3.89)

6

1.01

(0.32–3.23)

Pre-diagnostic statin use

 No

235

162

1.00

Ref.

20

1.00

Ref.

 Yes

186

114

0.72

(0.56–0.93)

14

0.66

(0.30–1.43)

Pre-diagnostic ADM group

 Metformin

77

46

1.15

(0.74–1.79)

5

1.85

(0.44–7.73)

 Othera

58

44

1.00

Ref.

4

1.00

Ref.

 Metformin and othera

100

67

1.21

(0.82–1.80)

6

1.19

(0.32–4.38)

 Insulin

82

59

1.49

(0.96–2.30)

7

1.61

(0.42–6.18)

 None

104

60

0.69

(0.46–1.03)

12

1.48

(0.46–4.78)

  1. All HRs were adjusted for the other factors in this table
  2. aother oral antidiabetic medication
  3. OC Ovarian cancer, HR Hazard ratio, 95% CI 95% confidence interval